Berlin, Mar 31 (efe-epa).- The Pfizer-BioNTech coronavirus vaccine is 100 percent effective in adolescents between 12 and 15 years old, according to the results of a phase 3 trials conducted on 2,260 people, the companies announced on Wednesday.
“In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses (…) and was well tolerated,” the German BioNTech pharmaceutical company said in a statement.
The next step is to apply for the United States FDA approval so that the teenagers aged between 12 and 15 can be inoculated “before the start of the next school year,” Albert Bourla, Chairman and Chief Executive Officer, Pfizer said.
During the trials involving children in the US between the ages of 12 and 15 years, no case has been detected among the vaccinated group, compared to 18 in the placebo group.
This shows “strong immunogenicity in a subset of adolescents one month after the second dose,” according to a statement by the two companies.
The side effects detected are similar to those shown by the individuals aged between 16 and 25 years, the statement added.
The trial results are “very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant,” Ugur Sahin, CEO, and Co-founder of BioNTech said.
The Pfizer-BioNTech vaccine was the first to be approved by the European Union in late December and proved to be 95 percent effective.
Both companies are planning to boost their vaccine production from 2 to 2.5 billion jabs to meet the increasing demand, according to the German company.
To date, BioNTech and Pfizer have provided over 2 million doses of the vaccine, and there have been orders placed for more than 1.4 billion doses to be produced by the end of the year. EFE-EPA